Evidence map›Paper›PMID 40463429›Full record

ArticleChemical science2025

Guided multi-objective generative AI to enhance structure-based drug design.

Amit Kadan, Kevin Ryczko, Erika Lloyd, Adrian Roitberg, Takeshi Yamazaki

Abstract read
In one paragraph

Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Applying Deep-Learning-DrivenJournal of medicinal chemistry · 2026
    Article
  3. RiboScreenBiomedicines · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amit KadanSandboxAQ Palo Alto CA USA amit.kadan@sandboxaq.com kevin.ryczko@sandboxaq.com takeshi.yamazaki@sandboxaq.com.ORCID https://orcid.org/0009-0001-9037-0915
Kevin RyczkoSandboxAQ Palo Alto CA USA amit.kadan@sandboxaq.com kevin.ryczko@sandboxaq.com takeshi.yamazaki@sandboxaq.com.ORCID https://orcid.org/0000-0001-6933-3856
Erika LloydSandboxAQ Palo Alto CA USA amit.kadan@sandboxaq.com kevin.ryczko@sandboxaq.com takeshi.yamazaki@sandboxaq.com.
Adrian RoitbergDepartment of Chemistry, University of Florida PO Box 117200 Gainesville Florida 32611-7200 USA.
Takeshi YamazakiSandboxAQ Palo Alto CA USA amit.kadan@sandboxaq.com kevin.ryczko@sandboxaq.com takeshi.yamazaki@sandboxaq.com.ORCID https://orcid.org/0000-0002-5714-764X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generative AI has the potential to revolutionize drug discovery. Yet, despite recent advances in deep learning, existing models cannot generate molecules that satisfy all desired physicochemical properties. Herein, we describe IDOLpro, a novel generative chemistry AI combining diffusion with multi-objective optimization for structure-based drug design. Differentiable scoring functions guide the latent variables of the diffusion model to explore uncharted chemical space and generate novel ligands

Identifiers

PMID40463429
PMCPMC12127851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.